The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 31, 2017

Filed:

Jun. 25, 2013
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Paul Reichert, Montville, NJ (US);

Winifred W. Prosise, Ramsey, NJ (US);

Peter Orth, New York, NY (US);

Chakravarthy Nachu Narasimhan, Scotch Plains, NJ (US);

Ramesh S. Kashi, Warren, NJ (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); A61K 39/39591 (2013.01); C07K 2299/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e. they maintain biological activity of the anti-huiL-23 antibody, such as anti-huiL-23p 19 antibody, longer than corresponding solution formulations.


Find Patent Forward Citations

Loading…